Key result
Calcium channel blockers, ACE inhibitors, and ARBs are associated with a lower prevalence of new-onset diabetes compared to diuretics and beta-blockers in treated hypertensive patients.
Why the study?
Do calcium channel blockers, ACE inhibitors, or ARBs reduce the risk of new-onset diabetes compared to diuretics and beta-blockers in treated hypertensive patients?
Do calcium channel blockers, ACE inhibitors, or ARBs reduce the risk of new-onset diabetes compared to diuretics and beta-blockers in treated hypertensive patients?
Different classes of antihypertensive drugs have varying effects on the risk of developing new-onset diabetes, with diuretics and beta-blockers posing a higher risk than CCBs, ACE inhibitors, and ARBs.
The development of new-onset diabetes is frequent during the follow-up of treated hypertensive patients. The prevalence of such an event seems to differ depending on the type of antihypertensive therapy used to control blood pressure. Diuretics and b-blockers and their association are particularly harmful in this regard. On the contrary, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, alone or in association with diuretics, are associated with a lower prevalence of this metabolic complication. These statements are confirmed by data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study. Long-term studies are required to determine the relevance of development of new-onset diabetes in treated hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Sierra et al. (2003) conducted an editorial in hypertension. Antihypertensive therapy was evaluated on New-onset diabetes. Calcium channel blockers, ACE inhibitors, and ARBs are associated with a lower prevalence of new-onset diabetes compared to diuretics and beta-blockers in treated hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: